FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
Portfolio Pulse from Vandana Singh
The FDA has approved Gilead Sciences Inc's (NASDAQ:GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. This makes Veklury the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. The approval was based on results from a Phase 1 study and from the Phase 3 REDPINE trial.
July 14, 2023 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's Veklury has been approved by the FDA for use in COVID-19 patients with severe renal impairment. This expands the potential market for the drug and could lead to increased sales.
The FDA approval expands the potential market for Veklury, as it can now be used in COVID-19 patients with severe renal impairment. This could lead to increased sales for Gilead, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100